Industry News (Vaccine Development)

Human Papillomavirus Vaccine Technology Acquired

Published in Vaccine Weekly, October 16th, 1995

MedImmune, Inc., Gaithersburg, Maryland, and the University of Rochester, New York, announced that MedImmune has licensed exclusive worldwide rights to human papillomavirus (HPV) vaccine technology developed at University of Rochester. This technology complements MedImmune's existing HPV vaccine program initiated in late 1992.

MedImmune also holds an exclusive license to certain HPV vaccine technology developed by Georgetown University. HPV, which causes genital warts and cervical cancer, is the most common sexually transmitted disease in the United States. There are currently no vaccines to prevent this potentially serious infection.

Pursuant to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry